MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Akebia Therapeutics Company Profile (NASDAQ:AKBA)

Consensus Ratings for Akebia Therapeutics (NASDAQ:AKBA) (?)
Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $16.71 (130.86% upside)

Analysts' Ratings History for Akebia Therapeutics (NASDAQ:AKBA)
Show:
DateFirmActionRatingPrice TargetActions
5/16/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Morgan StanleyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Needham & Company LLCLower Price TargetBuy$18.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$24.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$24.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/20/2016Credit SuisseInitiated CoverageNeutral$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2015NomuraReiterated RatingBuy$37.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Akebia Therapeutics (NASDAQ:AKBA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015($0.57)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.34)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.38)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Akebia Therapeutics (NASDAQ:AKBA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Akebia Therapeutics (NASDAQ:AKBA)
DateHeadline
06/26/16 02:22 PMAkebia Therapeutics, Inc. (AKBA) Broker Price Targets For The Coming Week - Fiscal Standard
06/25/16 02:25 PMAkebia Therapeutics Incorporated (NASDAQ:AKBA) Sellers Covered 4.1% of Their Shorts - Engelwood Daily
06/24/16 02:22 PMShare Volatility Check for: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Press Telegraph
06/24/16 09:46 AMAkebia Therapeutics Inc. (AKBA) Jumps 6.28% on June 23 - Equities.com
06/23/16 10:13 AMAkebia Therapeutics Inc. (AKBA) is Trading Lower on Unusual Volume for June 21 - Equities.com
06/21/16 03:07 PMAKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/21/16 07:12 AMStrong Buy Calls Count For Akebia Therapeutics, Inc. (NASDAQ:AKBA) At 3 - Investor Newswire
06/21/16 07:12 AMAkebia Therapeutics, Inc. (AKBA) Current Analyst Ratings - Fiscal Standard
06/13/16 02:22 PMTrend Of Rating Given To Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Investor Newswire
06/10/16 10:49 AMAkebia Therapeutics, Inc. (NASDAQ:AKBA) Earnings Preview: Should Investors Be Nervous? - iStreetWire
06/08/16 10:53 AMAkebia Therapeutics, Inc. (AKBA) Updated Price Targets - FTSE News
06/03/16 10:52 AMAkebia Therapeutics Inc (NASDAQ:AKBA) Given Average Recommendation of “Buy” from Analysts - Let Me Know About This
06/03/16 10:52 AMBroker Watchlist: Akebia Therapeutics, Inc. (AKBA) - Share Trading News
06/02/16 12:01 PMAkebia Therapeutics, Inc. :AKBA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/01/16 10:47 AMAkebia Therapeutics Incorporated (NASDAQ:AKBA) Shorted Shares Increased 0.12% After Market Selling - HNN - Akebia Therapeutics Incorporated (NASDAQ:AKBA) Shorted Shares Increased 0.12% After Market SellingHNNThe short interest to Akebia Therapeutics Incorporated's float is 16.35%. The stock increased 1.25% or $0.11 during the last trading session, hitting $8.91. Akebia Therapeutics Inc (NASDAQ:AKBA) has declined 2.09% since October 23, 2015 and is ...
05/30/16 09:19 PMBrean Capital Reiterates Buy Rating for Akebia Therapeutics Inc (AKBA) - Let Me Know About This - Brean Capital Reiterates Buy Rating for Akebia Therapeutics Inc (AKBA)Let Me Know About ThisAkebia Therapeutics logo Akebia Therapeutics Inc (NASDAQ:AKBA)'s stock had its “buy” rating reissued by equities research analysts at Brean Capital in a report released on Sunday. A number of other equities research analysts also recently commented on ...
05/30/16 09:19 PMBrean Capital Reiterates Buy Rating for Akebia Therapeutics Inc (AKBA) - Let Me Know About This - Brean Capital Reiterates Buy Rating for Akebia Therapeutics Inc (AKBA)Let Me Know About ThisAkebia Therapeutics logo Akebia Therapeutics Inc (NASDAQ:AKBA)'s stock had its “buy” rating reissued by equities research analysts at Brean Capital in a report released on Sunday. A number of other equities research analysts also recently commented on ...
05/23/16 12:12 PMAkebia Therapeutics (AKBA) Announces Positive Data from Vadadustat Drug-Interaction Study in CKD - StreetInsider.com - Akebia Therapeutics (AKBA) Announces Positive Data from Vadadustat Drug-Interaction Study in CKDStreetInsider.comAkebia Therapeutics, Inc. (Nasdaq: AKBA) presented positive results from a drug-drug interaction study of vadadustat, the Company's oral therapy for the treatment of anemia related to chronic kidney disease (CKD). The study demonstrated that vadadustat ...and more »
05/23/16 06:01 AM7:01 am Akebia Therapeutics announces 'positive' results from a drug-drug interaction study of vadadustat -
05/23/16 06:00 AMAkebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction - [Business Wire] - Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor , today presented positive results from a drug-drug interaction study of vadadustat, the Company’s oral therapy for the treatment of anemia related to chronic kidney disease .
05/19/16 12:06 AMRevenue Update on Akebia Therapeutics Inc(NASDAQ:AKBA) - Trade Calls - Revenue Update on Akebia Therapeutics Inc(NASDAQ:AKBA)Trade CallsAkebia Therapeutics Inc(NASDAQ:AKBA) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Company reported revenue of $0.00. Analysts estimated a revenue of $12.38M. Earnings per ...
05/17/16 06:41 PMAkebia Therapeutics Inc (AKBA) Jumps 5.91% on May 16 - Equities.com - Akebia Therapeutics Inc (AKBA) Jumps 5.91% on May 16Equities.comAkebia Therapeutics Inc (AKBA) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 5.91% to $8.24, representing a gain of $0.46 per share. Some 185,466 shares traded hands on 1,483 trades, compared with an ...
05/16/16 11:48 PMAkebia Therapeutics, Inc. (AKBA) Broker Price Targets For The Coming Week - Share Trading News - Akebia Therapeutics, Inc. (AKBA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Akebia Therapeutics, Inc. (AKBA). The latest reports which are currently in issue on Sunday 15th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
05/16/16 06:32 AMAkebia to Present at the 2016 UBS Global Healthcare Conference - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible ...
05/10/16 07:18 PMConsensus Rating Review for Akebia Therapeutics, Inc. (NASDAQ:AKBA) - B.O.D.Y Confidential - Consensus Rating Review for Akebia Therapeutics, Inc. (NASDAQ:AKBA)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1.3 on shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/09/16 07:06 PMBiotech Movers and Shakers: Akebia Therapeutics Inc (NASDAQ:AKBA) and Clovis Oncology Inc (NASDAQ:CLVS) - Market Exclusive - Market ExclusiveBiotech Movers and Shakers: Akebia Therapeutics Inc (NASDAQ:AKBA) and Clovis Oncology Inc (NASDAQ:CLVS)Market ExclusiveThe net loss was down expectations, and this is why the company sold off, but in the grand scheme of things, Akebia is in a pretty strong position. Cash will carry it through to the middle of next year, and with a late stage trial set to begin both in ...
05/08/16 08:44 PMBroker Outlook For The Week Ahead Akebia Therapeutics, Inc. (AKBA) - Share Trading News - Broker Outlook For The Week Ahead Akebia Therapeutics, Inc. (AKBA)Share Trading NewsThe Company's lead product candidate, AKB-6548, is being developed as a once-daily, oral therapy. It has completed a Phase IIb study demonstrating that AKB-6548 can raise hemoglobin levels in non-dialysis patients with anemia related to chronic kidney ...What Analyst Suggest Today? Array BioPharma Inc. (NASDAQ:ARRY), Akebia Therapeutics, Inc. (NASDAQ:AKBA)WsNews 4investorsall 2 news articles »
05/06/16 07:19 PMRelative Strength Alert For Akebia Therapeutics - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Akebia Therapeutics Inc (AKBA) entered into oversold territory, hitting an RSI reading of 28.9, after changing hands as low as $7.60 per share.
05/05/16 08:07 PMEarnings Outlook on Akebia Therapeutics, Inc. (NASDAQ:AKBA) - B.O.D.Y Confidential - Earnings Outlook on Akebia Therapeutics, Inc. (NASDAQ:AKBA)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Akebia Therapeutics, Inc. (NASDAQ:AKBA)'s next earnings release which is expected to be posted on or around 2016-05-09. Sell-side research firms on Wall Street are expecting that the company will post EPS of ...and more »
05/05/16 05:04 PMAkebia Therapeutics reports 1Q loss -
05/05/16 03:21 PMAkebia Announces First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - - Reaches Alignment with FDA and EMA on INNOVATE Phase 3 Program - - Announces Positive Data from Japanese Ethnobridging Study for Vadadustat - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, ...
05/05/16 03:15 PMAKEBIA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/04/16 07:15 PMAkebia Therapeutics Incorporated (NASDAQ:AKBA) Shorted Shares Increased By 1.59% - B.O.D.Y Confidential - Akebia Therapeutics Incorporated (NASDAQ:AKBA) Shorted Shares Increased By 1.59%B.O.D.Y ConfidentialThe short interest to Akebia Therapeutics Incorporated's float is 18.74%. The stock is down 3.21% or $0.3 after the news, hitting $9.06 per share. About 182,072 shares traded hands. Akebia Therapeutics Inc (NASDAQ:AKBA) has declined 2.50% since ...and more »
05/04/16 12:21 AMAverage Analyst Rating for Akebia Therapeutics, Inc. (NASDAQ:AKBA) - B.O.D.Y Confidential - Average Analyst Rating for Akebia Therapeutics, Inc. (NASDAQ:AKBA)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.3 on Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
04/27/16 07:54 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA) Wall Street Rating in Focus - News Tribune - Akebia Therapeutics, Inc. (NASDAQ:AKBA) Wall Street Rating in FocusNews TribuneZacks.com, founded by Len Zacks, a Mathematics Ph.D. from M.I.T. who discovered that earnings estimate revisions are the most powerful force impacting stock prices, track 5 equity research firms that cover shares of Akebia Therapeutics, Inc.and more »
04/26/16 07:16 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA) Share Rating Recap - B.O.D.Y Confidential - Akebia Therapeutics, Inc. (NASDAQ:AKBA) Share Rating RecapB.O.D.Y ConfidentialShares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...
04/26/16 06:00 AMAkebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings - [Business Wire] - Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor , today announced that Phase 2 results for vadadustat in dialysis patients with anemia related to chronic kidney disease , including new pharmacokinetic data, will be presented in a poster presentation at the National Kidney ...
04/25/16 09:45 PMAkebia Therapeutics Incorporated (NASDAQ:AKBA) Sellers Increased By 4.3% Their Shorts - B.O.D.Y Confidential - Akebia Therapeutics Incorporated (NASDAQ:AKBA) Sellers Increased By 4.3% Their ShortsB.O.D.Y ConfidentialThe short interest to Akebia Therapeutics Incorporated's float is 18.45%. The stock increased 1.25% or $0.12 on April 22, hitting $9.69. Akebia Therapeutics Inc (NASDAQ:AKBA) has declined 11.10% since September 17, 2015 and is downtrending.and more »
04/24/16 09:34 PMNext Weeks Broker Price Targets For Akebia Therapeutics, Inc. (AKBA) - Share Trading News - Next Weeks Broker Price Targets For Akebia Therapeutics, Inc. (AKBA)Share Trading News03/15/2016 – Akebia Therapeutics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 18 price target on the stock. 01/21/2016 – Credit Suisse began new coverage on Akebia Therapeutics, Inc. giving the company a ...and more »
04/23/16 07:05 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA) Has Been Given An ABR Of 1.3 - RealistInvestor.com - Akebia Therapeutics, Inc. (NASDAQ:AKBA) Has Been Given An ABR Of 1.3RealistInvestor.comAnalysts have a positive outlook on Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock. As of 2016-04-23, the stock has been placed an ABR of 1.3. This number comes on a scale of 1 to 5, where one suggests a strong buy call and five indicates Strong Sell.and more »
04/21/16 08:50 PMHow Many Akebia Therapeutics Inc (NASDAQ:AKBA)'s Analysts Are Bullish? - The Post - How Many Akebia Therapeutics Inc (NASDAQ:AKBA)'s Analysts Are Bullish?The PostOut of 7 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Akebia Therapeutics Inc has been the topic of 10 analyst reports since August 13, 2015 according to ...Latest Analyst Ratings For Akebia Therapeutics, Inc. (AKBA)Share Trading Newsall 2 news articles »
04/20/16 08:11 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA): Where are Shares Headed? - News Tribune - Akebia Therapeutics, Inc. (NASDAQ:AKBA): Where are Shares Headed?News TribuneResearch analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares have provided price target projections on the popular stock. They project that the shares are expected to reach $19.8 within the upcoming year. This consensus number they've ...and more »
04/20/16 02:28 AMLatest Analyst Ratings For Akebia Therapeutics, Inc. (AKBA) - Share Trading News - Latest Analyst Ratings For Akebia Therapeutics, Inc. (AKBA)Share Trading News03/15/2016 – Akebia Therapeutics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 18 price target on the stock. 01/21/2016 – Credit Suisse began new coverage on Akebia Therapeutics, Inc. giving the company a ...and more »
04/13/16 07:40 AMIncreased Earnings Estimates Seen for Akebia Therapeutics (AKBA): Can It Move Higher? -
03/18/16 12:04 PMAKEBIA THERAPEUTICS, INC. Financials -
03/15/16 02:59 PMAkebia Therapeutics (AKBA) Stock Down on Q4 Results -
03/15/16 03:13 AMEdited Transcript of AKBA earnings conference call or presentation 14-Mar-16 8:30pm GMT -
03/14/16 03:30 PMAkebia Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today -
03/14/16 03:21 PMAKEBIA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report -
03/09/16 11:33 AMAKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
About Akebia Therapeutics

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AKBA
  • CUSIP:
Key Metrics:
  • Previous Close: $7.47
  • 50 Day Moving Average: $8.3123
  • 200 Day Moving Average: $8.8402
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $130.80M
  • Current Quarter EPS Consensus Estimate: $-2.5400 EPS
Additional Links:
Akebia Therapeutics (NASDAQ:AKBA) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha